This work was supported by the Funds of National Natural Science Foundation of China (82060728), Guizhou Provincial Science and Technology Department (MS [2025-380], Thousand Talents Program), Talents of Guizhou Science and Technology Platform [2021]1350-009, Zunyi Science and Technology Bureau (HZ-2023-173, HZ-2023-09, [2024] No
These benefits may ultimately prove more important than weight loss percentages for overall health outcomes
Hyperuricemia and gout reduction by SGLT2 inhibitors in diabetes and heart failure
Nearly a decade on trends, risk factors and policy implications in global obesity
Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study
Roughly a quarter to 40% of the weight people lose on Ozempic, Wegovy, and Mounjaro is lean mass: muscle, organ tissue, and bone